Anika Therapeutics, Inc. Stock News

NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

Anika Therapeutics, Inc. ( ANIK ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Matt Hall Cheryl Blanchard - President, CEO & Director Stephen Griffin - Executive VP, CFO & COO Conference Call Participants Michael Petusky - Barrington Research Associates, Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Anika's third quar...

Commercial Channel revenue up 22% with continued strong Integrity ™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 mi...

BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in  Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in  Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

BEDFORD, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on September 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise...

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options